Kanamycin B
bekanamycin
CAS: 4696-76-8
Molecular Formula: C18H37N5O10
Kanamycin B - Names and Identifiers
| Name | bekanamycin |
| Synonyms | kdm NK 1006 nebramycinv Bekanamycin bekanamycin Kanamycin B kanendomycin nebramycinfactor5 Nebramycin factor 5 d-streptamine,o-3-amino-3-deoxy-alpha-d-glucopyranosyl-(1-4)-o-(2,6-diamino-2, 4,6-diamino-3-[(3-amino-3-deoxyhexopyranosyl)oxy]-2-hydroxycyclohexyl 2,6-diamino-2,6-dideoxyhexopyranoside (2R,3S,4R,5R,6R)-5-Amino-2-(aminomethyl)-6-[(1R,2S,3S,4R,6S)-4,6-diamino-3-[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxyoxane-3,4-diol |
| CAS | 4696-76-8 |
| EINECS | 225-170-5 |
| InChI | InChI=1/C18H37N5O10/c19-2-6-11(26)12(27)9(23)17(30-6)32-15-4(20)1-5(21)16(14(15)29)33-18-13(28)8(22)10(25)7(3-24)31-18/h4-18,24-29H,1-3,19-23H2 |
Kanamycin B - Physico-chemical Properties
| Molecular Formula | C18H37N5O10 |
| Molar Mass | 483.51 |
| Density | 1.3771 (rough estimate) |
| Melting Point | 178-182° (dec) |
| Boling Point | 580.49°C (rough estimate) |
| Specific Rotation(α) | D18 +130° (c = 0.5 in water); D21 +114° (c = 0.98 in water) |
| Flash Point | 442.3°C |
| Solubility | Aqueous Acid (Slightly), Methanol (Slightly, Heated, Sonicated), Water (Sparingl |
| Vapor Presure | 3.43E-30mmHg at 25°C |
| Appearance | Solid |
| Color | Crystals |
| pKa | 13.07±0.70(Predicted) |
| Storage Condition | under inert gas (nitrogen or Argon) at 2–8 °C |
| Stability | Hygroscopic |
| Refractive Index | 1.7600 (estimate) |
| Use | It is an antibiotic drug and an intermediate for the production of deca-star sulfate and abecacin sulfate |
| In vitro study | Bekanamycin (Kanamycin B) is a precursor for semisynthetic antibiotics such as Arbekacin and Dibekacin and is generally extracted from the broth of S. kanamyceticus . Bekanamycin (Kanamycin B) in a concentration-dependent fashion reduces reversibly the quantal content of the end-plate potentials while it has no observable effect on the configuration of the extracellularly recorded presynaptic action potential. The reduction in evoked transmitter release produced by Bekanamycin could be antagonized either by increasing the external calcium concentration or by drugs like the aminopyridines which are to greatly enhance transmitter release from motor nerve terminals. Bekanamycin exerts potent inhibitory effects on transmitter release probably by interfering with the influx of calcium that occurs during depolarization of motor nerve terminals. |
Kanamycin B - Risk and Safety
| Toxicity | LD50 i.v. in mice: 136 mg/kg (Wakazawa) |
Supplier List
Spot supply
Product Name: Tobramycin Impurity 1 (Tobramycin EP Impurity A) (Kanamycin B) Visit Supplier Webpage Request for quotationCAS: 4696-76-8
Tel: 0714-3999186
Email: 2853786052@qq.com
Mobile: 86+15671228036
QQ: 2853786052
Wechat: 15671228036
Spot supply
Product Name: Bekanamycin Visit Supplier Webpage Request for quotationCAS: 4696-76-8
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
Spot supply
Product Name: Tobramycin Impurity 1 (Tobramycin EP Impurity A) (Kanamycin B) Visit Supplier Webpage Request for quotationCAS: 4696-76-8
Tel: 0714-3999186
Email: 2853786052@qq.com
Mobile: 86+15671228036
QQ: 2853786052
Wechat: 15671228036
Spot supply
Product Name: Bekanamycin Visit Supplier Webpage Request for quotationCAS: 4696-76-8
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
View History